Gut-Liver Axis and Omni-Biotic Hetox Publications

Illustration of the Gut-Liver Axis showing the interaction between the gut microbiome and liver cells

The gut and liver communicate bidirectionally through the biliary tract, portal vein and systemic circulation. For its part, the liver communicates with the intestines through the release of bile acids and active molecules. In the intestine, metabolic products of friendly, resident gut microbes also influence liver function.

Clinical studies have demonstrated the gut-liver and detoxification power of OMNi-BiOTiC® Hetox with outcomes including improved liver function and cardiometabolic parameters as well as decreased toxin load.

Read This Next

Human Clinical Trials on Final Formulation

The following studies were performed on the commercial Omni-Biotic formulation available in the US market. In some cases the brand name will differ based on the European marketed product, but probiotic strains and formulation are identical.

Effects of a synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study.
Author/Year: Horvath et al; 2019
Study Type: Pilot Study
Key findings include:
Improvements in:
  • Hip circumference
  • Zonulin levels
  • Lipoprotein(a)
Read full study
Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial
Author/Year: Sabico et al., 2018
Study Type: Randomized Controlled Trial (RCT)
Key findings include:
  • Reduced circulating endotoxin levels (70%)
  • Reduced metabolic markers: glucose (38%), insulin (38%), HOMA-IR (64%), triglycerides (48%), total cholesterol (19%), total/HDL-cholesterol ratio (19%)
  • Reduced inflammatory markers: TNF-α (67%), IL-6 (77%), CRP (53%), resistin (53%)
Read full study
Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial
Author/Year: Szulinska et al., 2018
Study Type: Randomized Controlled Trial (RCT)
Key findings include:
Improvements in:
  • Improvements in lipopolysaccharide levels
  • Reduced waist circumference and fat mass/subcutaneous fat
  • Improvements in total cholesterol, triglycerides, and low-density lipoprotein
  • Improved glucose and HOMA-IR levels
Read full study
Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial
Author/Year: Sabico et al., 2017
Study Type: Randomized Controlled Trial (RCT)
Key findings include:
  • Reduced abdominal adiposity (hip:waist ratio)
  • Improved HOMA-IR
  • Demonstrated safety and efficacy in medication naive T2DM
Read full study
Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis
Author/Year: Horvarth et al., 2016
Study Type: Randomized Controlled Trial (RCT)
Key findings include:
  • Increased neutrophil resting burst and neopterin levels
  • Improvement in liver function
  • Demonstrated safety and efficacy in stable liver cirrhosis
Read full study
The effects of the probiotic mixture on migraine: results of an open-label pilot study.
Author/Year: de Roos et al; 2015
Study Type: Pilot Study
Key findings include:
Improvements in:
  • Migraine intensity
  • Migraine frequency
  • Migraine Disability Assessment Scale (MIDAS)
Read full study

Reviews

The following papers are not specific to Omni-Biotic products but are provided here for informational and educational purposes.

"The gut-liver axis and the intersection with the microbiome"
Year Published: 2018
Study Type: review article
Related Omni-Biotic Formulation: Hetox

This review discusses gut-liver communications in various forms of liver disease and the potential to use the microbiome to determine the stage of liver disease as well as predicting the effects of dietary and pharmaceutical interventions.
Read full study